{Reference Type}: Journal Article
{Title}: Sputum interleukin-6 level as a marker of severity during acute chest syndrome in children with sickle cell disease.
{Author}: Mayrand L;Elie J;Pinhas Y;Rignault-Bricard R;Taylor M;Brice J;de Montalembert M;Heilbronner C;Beranger A;Angyalosy S;Chhun S;Maciel TT;Hermine O;Allali S;
{Journal}: Br J Haematol
{Volume}: 205
{Issue}: 1
{Year}: 2024 Jul 23
{Factor}: 8.615
{DOI}: 10.1111/bjh.19561
{Abstract}: Acute chest syndrome (ACS) is a leading cause of morbimortality in sickle cell disease (SCD). In this prospective observational study, we investigated sputum interleukin-6 (IL-6) level as an ACS severity marker during 30 ACS episodes in 26 SCD children. Sputum IL-6 levels measured within the first 72 h of hospitalisation for ACS were significantly higher in patients with oxygen requirement ≥2 L/min, ventilation (invasive and/or non-invasive) length ≥5 days, bilateral and/or extensive opacities on chest X-ray or erythrocytapheresis requirement. Sputum IL-6 could serve as an ACS severity marker to help identify patients requiring targeted anti-inflammatory treatments such as tocilizumab.